All In Biotech

Drug Trial Radar · NCT04463251

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

International, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Last checked: Nov 20, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Dec 7, 2020

Primary completion

Nov 3, 2021

Study completion Oct 10, 2022

Sponsor

Lead sponsor
R-Pharm Overseas, Inc.Industry
Sponsor type
Industry
Collaborators
Cromos Pharma LLC; Data Management 365; Keystat, LLC; R-Pharm; K-Research, LLC
First posted
Jul 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial infarction (STEMI)

Conditions

  • Acute ST Segment Elevation Myocardial Infarction

Interventions

  • RPH-104 80 mgBiological

    solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial

  • PlaceboDrug

    Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Multiple Imputation Procedure)Time frame: Day 1 until Day 14
  2. High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (сomplete Cases)Time frame: Day 1 until Day 14
  3. High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Sensitivity Analysis, Multiple Imputation Procedure)Time frame: Day 1 until Day 14
  4. High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Sensitivity Analysis, Complete Cases)Time frame: Day 1 until Day 14

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Virginia Health System

    Charlottesville, Virginia

  • VCU Health-Virginia Commonwealth University Health

    Richmond, Virginia

  • State Budgetary Healthcare Institution of Moscow "City Clinical Hospital named after V.V. Vinogradov of Moscow Healthcare Department"

    Moscow, Russia

  • State Institution of Healthcare in Moscow "City Clinical Hospital № 51 Moscow Health Department"

    Moscow, Russia

  • Federal State Budgetary Institution "National Medical Research Center for Cardiology" of the Ministry of Healthcare of the Russian Federation

    Moscow, Russia

  • State Budgetary Healthcare Institution of Moscow "City Clinical Hospital named after V.V. Veresaev of Moscow Healthcare Department"

    Moscow, Russia

  • State Autonomous Healthcare Institution of the Perm Territory "City Clinical Hospital No. 4"

    Perm, Russia

  • Ryazan State Medical University n.a. academician I.P. Pavlov on the basis of Regional Clinical cardiology Dispensary

    Ryazan, Russia

  • St. Petersburg State Budgetary Healthcare Institution "Saint Martyr Elizabeth City Hospital"

    Saint Petersburg, Russia

  • The State Budgetary Health Care Institution of the Yaroslavl Region "Regional Clinical Hospital"

    Yaroslavl, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.